- In March 2024, Fidia Farmaceutici S.p.A., a leading Italy-based biopharmaceutical company, announced the expansion of its hyaluronic acid (HA) production facility in Abano Terme to meet rising European demand for viscosupplementation therapies. The upgraded site is expected to increase output of single-injection and cross-linked HA formulations, reinforcing Fidia's leadership in the OA treatment segment and improving supply chain responsiveness across major European markets
- In February 2024, Anika Therapeutics, Inc. partnered with select orthopedic clinics in Germany and France to roll out a clinical support initiative promoting early-stage viscosupplementation for knee osteoarthritis. The program includes physician training and patient education to drive awareness and adoption of Anika’s HA-based injections, aligning with broader goals to reduce reliance on NSAIDs and delay surgical interventions
- In January 2024, TRB Chemedica AG introduced a new generation of high molecular weight hyaluronic acid under the brand name ViscoFlow Pro across Switzerland and the Benelux region. The product launch highlights growing interest in premium viscosupplementation therapies that offer prolonged efficacy and improved patient outcomes with fewer injections. This move supports TRB’s strategy to strengthen its European orthopedic portfolio
- In November 2023, Bioventus Inc. completed a multi-country post-market clinical evaluation of its Durolane single-injection HA therapy across Spain, the UK, and Italy. Results demonstrated high patient satisfaction and clinically significant improvements in pain and mobility, bolstering clinical evidence supporting broader reimbursement discussions and real-world use in European outpatient settings
- In October 2023, Seikagaku Corporation, through its European distribution partner, expanded access to its SUPARTZ FX viscosupplementation solution in Poland and Eastern Europe. The expansion supports the company’s strategic aim to reach underpenetrated markets with growing OA burdens and limited surgical alternatives, contributing to regional equity in OA care through minimally invasive injectable solutions
